Cargando…

Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden

OBJECTIVES: TNF inhibitors (TNFis) and IL inhibitors are effective treatments for PsA. Treatment non-persistence (drug survival, discontinuation) is a measure of effectiveness, tolerability and patient satisfaction or preferences in real-world clinical practice. Persistence on these treatments is no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geale, Kirk, Lindberg, Ingrid, Paulsson, Emma C, Wennerström, E Christina M, Tjärnlund, Anna, Noel, Wim, Enkusson, Dana, Theander, Elke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772250/ https://www.ncbi.nlm.nih.gov/pubmed/33409449 http://dx.doi.org/10.1093/rap/rkaa070

Ejemplares similares

Corrigendum to: Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden
por: Geale, Kirk, et al.
Publicado: (2021)

Incidence of Psoriatic Arthritis in Patients with Skin Psoriasis and Associated Risk Factors: A Retrospective Population-based Cohort Study in Swedish Routine Clinical Care
por: LINDBERG, Ingrid, et al.
Publicado: (2020)

Validity of Diagnostic Codes and Prevalence of Physician-Diagnosed Psoriasis and Psoriatic Arthritis in Southern Sweden – A Population-Based Register Study
por: Löfvendahl, Sofia, et al.
Publicado: (2014)

Treatment persistence of biologics among patients with psoriatic arthritis
por: Haddad, Amir, et al.
Publicado: (2021)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
por: Gossec, Laure, et al.
Publicado: (2022)

How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden
por: Geale, Kirk, et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2023)

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
por: Van Kuijk, Arno W R, et al.
Publicado: (2023)

Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial
por: Tillett, William, et al.
Publicado: (2023)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis
por: Löfvendahl, Sofia, et al.
Publicado: (2017)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
por: Valenzuela, Fernando, et al.
Publicado: (2021)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Macrophage dysfunction in Psoriatic Arthritis
por: Wenink, Mark H, et al.
Publicado: (2011)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics
por: Silvy, Florent, et al.
Publicado: (2015)

Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
por: Olszewska, Barbara, et al.
Publicado: (2018)

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
por: Thibodeaux, Quinn, et al.
Publicado: (2019)

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)

Medication persistence for psoriatic arthritis in a Brazilian real-world setting
por: Ribeiro da Silva, Michael Ruberson, et al.
Publicado: (2019)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2013)

Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
por: Pai, Ganesh, et al.
Publicado: (2017)

Economic impact of biologic utilization patterns in patients with psoriatic arthritis
por: Schwartzman, Sergio, et al.
Publicado: (2017)

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
por: Murage, Mwangi J, et al.
Publicado: (2018)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Psoriatic Arthritis: An Update
por: Lloyd, Peter, et al.
Publicado: (2012)

Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden
por: Landgren, Anton Jonatan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_69dvbviov69kpij7fe9v28ts32